What are the main COVID-19 variants? How can they affect vaccine responses?
20 March 2026. Related: COVID-19: vaccine research, COVID-19: transmission & prevention, COVID-19.
2026
CROI 2026: i-Base reports from this essential meeting
13 March 2026. Related: Conference reports.
CROI 2026: GLP-1 weight loss drugs include potential immune benefits in gut tissue
13 March 2026. Related: Conference reports, Weight, diabetes, metabolic complications, Coinfections and complications.
CROI 2026: Australian study of 4CMenB vaccine fails to protect gay men against gonorrhoea
10 March 2026. Related: Conference reports, Coinfections and complications.
CROI 2026: Pritelivir active against drug resistant herpes in phase 3 study
9 March 2026. Related: Conference reports, Coinfections and complications.
GLP-1 receptor agonists reduce substance use disorder: a role for addiction to chemsex drugs?
6 March 2026. Related: Early access, Special reports, Side effects, Coinfections and complications.
Two cases of severe hyperglycemia with injectable CAB/RPV-LA
5 March 2026. Related: Journal scan, Early access, Side effects.
Continued assaults on LGBTQI people in Uganda: appeal against AHA to go ahead
4 March 2026. Related: Early access, Treatment access, Activism & advocacy.
CROI 2026: Community breakfast webinars now online
1 March 2026. Related: Conference reports, Activism & advocacy.
Future meetings and webinars 2026
1 March 2026. Related: Future meetings.
CROI 2026: US activist Peter Staley opens CROI: we must all be activists until the next US administration
27 February 2026. Related: Conference reports, Activism & advocacy.
CROI 2026: Statement in support of science
27 February 2026. Related: Conference reports, Activism & advocacy.
CROI 2026: Once-daily oral BIC/LEN simplifies ART for those on complex combinations
25 February 2026. Related: Conference reports, Antiretrovirals.
CROI 2026: Islatravir PrEP didn’t protect against M184V mutation in macaque study
24 February 2026. Related: Conference reports, HIV prevention and transmission, Drug resistance.
CROI 2026: 11 mg dose selected for once-monthly MK-8527 for phase 3 PrEP studies
24 February 2026. Related: Conference reports, HIV prevention and transmission.
CROI 2026: Continued HIV protection from 2:1:1 PrEP dosing in gay and bisexual men in Paris
24 February 2026. Related: Conference reports, HIV prevention and transmission.
CROI 2026: Overview and research to watch out for
23 February 2026. Related: Conference reports.
CROI 2026: Introduction and main themes
21 February 2026. Related: Conference reports.
HPV and anal cancer in HIV+ gay men: new campaign in Manchester: anal HPV in gay men on PrEP
7 February 2026. Related: Journal scan, Coinfections and complications, Cancer and HIV.
US funding cuts set to drive 23 million excess deaths in the poorest countries by 2030
5 February 2026. Related: Journal scan, Early access, Treatment access.
Cobicistat (Tybost) discontinuation in UK by the end of 2026
29 January 2026. Related: Early access, Treatment alerts, Treatment access.
Do ATIs in HIV cure-related studies cause anxiety?
27 January 2026. Related: Journal scan, Early access, Cure-related research.
The Morning After: new podcast interviews UK community activists
25 January 2026. Related: Activism & advocacy, On the web.
Achieving greater HIV viral suppression and reducing stimulant use in San Francisco pilot programme
12 January 2026. Related: Journal scan, Early access, Coinfections and complications, Activism & advocacy.
Cancer and women living with HIV: results from D:A:D and RESPOND support including screening in routine HIV care
11 January 2026. Related: Journal scan, Early access, Women's health, Cancer and HIV.
Confirmed safety of kidney transplant when both recipient and donor are HIV positive
11 January 2026. Related: Journal scan, Early access, Coinfections and complications, Cancer and HIV, Hepatitis coinfection.
Neutralising antibodies wane two years after mpox infection or vaccination: protection persists
10 January 2026. Related: Journal scan, Early access, mpox.